Jupiter Neurosciences (JUNS) began trading on the Nasdaq on Tue 3 Dec 24

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products primarily for the treatment of neuroinflammation. It is developing JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. 

The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 4
• Incorporated in 2015 
• Headquartered in Jupiter, Florida
• https://jupiterneurosciences.com/

Ticker: JUNS

 

One and two weeks later: